基于脂肪因子探析中医药治疗肥胖的研究进展
Research Progress in Traditional Chinese Medicine for Obesity Treatment from the Perspective of Adipokines
DOI: 10.12677/tcm.2026.1510608, PDF,   
作者: 刘飞宇*：黑龙江中医药大学研究生院，黑龙江 哈尔滨；任 那#：黑龙江中医药大学附属第一医院内分泌二科，黑龙江 哈尔滨
关键词: 肥胖；脂肪因子；中医药；研究进展；Obesity； Adipokines； Traditional Chinese Medicine； Research Progress
摘要: 肥胖如今已成为全中国备受关注的重大公共健康难题，其发病机制与脂肪组织内分泌功能的失调紧密相连。其中脂肪因子作为脂肪组织分泌的关键信号分子，在能量代谢、炎症反应及胰岛素抵抗中发挥着核心的调控作用。中医药在肥胖防治中有着千年的临床经验，具有多靶点协同、系统性调控的优势。本文系统阐述了脂肪因子在肥胖病理进程中的作用，重点阐述中医药(单味药及其活性成分、经典复方、针灸等中医疗法)通过调节脂肪因子的表达与功能干预叙述其对于肥胖治疗的最新研究进展。此外，深入剖析了当前相关研究的优势以及不足之处，并对未来的研究方向进行了展望，旨在为深入揭示中医药抗肥胖的作用机制以及开发新型防治策略提供坚实的理论支撑。
Abstract: Obesity has now become a major public health problem that attracts much attention throughout China, and its pathogenesis is closely related to the disorder of endocrine function in adipose tissue. Among them, adipokines, as key signaling molecules secreted by adipose tissue, play a core regulatory role in energy metabolism, inflammatory response and insulin resistance. Traditional Chinese medicine has a long history in the prevention and treatment of obesity and has the advantages of multi-target and overall regulation. This article systematically expounds the role of adipokines in the pathological process of obesity, with a focus on elaborating the latest research progress of traditional Chinese medicine (single drugs and their active ingredients, classic compound prescriptions, acupuncture, etc.) in the treatment of obesity through regulating the expression and functional intervention of adipokines. In addition, the advantages and shortcomings of the current related research were deeply analyzed, and the future research directions were prospected, aiming to provide a solid theoretical support for deeply revealing the mechanism of action of traditional Chinese medicine in anti-obesity and developing new prevention and treatment strategies.
文章引用：刘飞宇, 任那. 基于脂肪因子探析中医药治疗肥胖的研究进展[J]. 中医学, 2026, 15(10): 709-715. https://doi.org/10.12677/tcm.2026.1510608

参考文献

[1] 肥胖症诊疗指南(2024年版) [J]. 中国循环杂志, 2025, 40(1): 6-30.
[2] 张梓涵, 杨丽霞, 贺云. 脂肪因子、炎症因子与胰岛素抵抗分子机制研究进展[J]. 中医临床研究, 2021, 13(28): 144-148.
[3] 王玮. 代谢综合征与脂肪因子研究进展[J]. 齐齐哈尔医学院学报, 2015, 36(2): 245-247.
[4] Jung, U.J. and Choi, M.S. (2014) Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 15, 6184-6223.
https://doi.org/10.3390/ijms15046184
[5] 中国专家发现肝脏中的新型“肥胖因子” [J]. 上海医药, 2019, 40(11): 36.
[6] 关亚群. 脂肪因子内脂素和Chemerin在代谢综合征发病机制中的作用研究[D]: [博士学位论文]. 乌鲁木齐: 新疆医科大学, 2011.
[7] Yang, L., Yin, R., Shan, Z., Feng, A., Li, K., Wang, Y., et al. (2025) Adipocyte-Secreted ANGPTL2 Promotes Hyperuricemia through Inhibiting AKT/ABCG2 Signaling. Free Radical Biology and Medicine, 233, 209-225.
https://doi.org/10.1016/j.freeradbiomed.2025.03.048
[8] 张莉唯, 刘喜明, 付守强, 等. 基于“中土之制”探讨黄连调节脂肪组织糖脂代谢的作用机制[J]. 中医学报, 2023, 38(7): 1410-1415.
[9] 崔建中, 孙中贺, 李剑, 等. 腹部推拿联合黄连膏外用治疗肥胖2型糖尿病的临床观察[J]. 长春中医药大学学报, 2024, 40(11): 1229-1233.
[10] 肖先, 李春燕, 薛金涛. 大黄的主要化学成分及药理作用研究进展[J]. 新乡医学院学报, 2024, 41(5): 486-490+496.
[11] 刘远洋, 陆益平, 叶嘉焕, 等. 大黄蒽醌类化合物及其衍生物对脂质代谢作用的机制分析[J]. 世界中医药, 2024, 19(18): 2709-2715+2724.
[12] Fang, J.Y., Huang, T.H., Chen, W.J., Aljuffali, I.A. and Hsu, C.Y. (2022) Rhubarb Hydroxyanthraquinones Act as Antiobesity Agents to Inhibit Adipogenesis and Enhance Lipolysis. Biomedicine & Pharmacotherapy, 146, Article 112497.
https://doi.org/10.1016/j.biopha.2021.112497
[13] Bradford, P.G. (2013) Curcumin and Obesity. BioFactors, 39, 78-87.
https://doi.org/10.1002/biof.1074
[14] 程亚青, 刘爱萍, 李佟, 等. 姜黄素通过调节p38 MAPK通路抑制前脂肪细胞3T3-F442A成脂分化[J]. 吉林化工学院学报, 2024, 41(7): 65-71.
[15] 石莹莹, 沙纪越, 李志满, 等. 基于AMPK信号通路探讨人参皂苷对脂质代谢调控的研究进展[J/OL]. 特产研究: 1-7.
https://www.chndoi.org/Resolution/Handler?doi=10.16720/j.cnki.tcyj.2023.233, 2025-06-11.
[16] 旷昕, 杨铮, 吴地尧, 等. 中医药通过干预细胞自噬治疗肥胖的研究进展[J]. 中药药理与临床, 2024, 40(1): 106-112.
[17] Sun, Q.W., Lian, C.F., Chen, Y.M., Ye, J., Chen, W., Gao, Y., et al. (2022) Ramulus Mori (Sangzhi) Alkaloids Ameliorate Obesity-Linked Adipose Tissue Metabolism and Inflammation in Mice. Nutrients, 14, Article 5050.
https://doi.org/10.3390/nu14235050
[18] Chen, Y.M., Lian, C.F., Sun, Q.W., Wang, T.T., Liu, Y.Y., Ye, J., et al. (2022) Ramulus Mori (Sangzhi) Alkaloids Alleviate High-Fat Diet-Induced Obesity and Nonalcoholic Fatty Liver Disease in Mice. Antioxidants, 11, Article 905.
https://doi.org/10.3390/antiox11050905
[19] 王晨, 班翔, 刘佳星, 等. 茶饮改善高脂饮食诱导的肥胖小鼠的代谢紊乱[J]. 复旦学报(医学版), 2025, 52(3): 393-402.
[20] 何若菡, 孙蕾蕾, 王浩田, 等. 茶多酚抗肥胖作用研究进展[J]. 茶叶学报, 2022, 63(2): 120-126.
[21] 李亚娟, 沈小璇, 袁婕. 防己黄芪汤联合循经推腹法治疗脾虚湿阻型单纯性肥胖疗效观察[J]. 现代中西医结合杂志, 2020, 29(26): 2924-2927.
[22] 王丽, 何毅豪, 胡星园, 等. 基于UHPLC-Q-TOF-MS/MS及网络药理学探讨葛根芩连汤治疗代谢综合征的潜在作用机制[J]. 中药新药与临床药理, 2022, 33(4): 484-491.
[23] Li, Y., Ye, Z., Zhao, Y., Xu, B., Xue, W., Wang, Z., et al. (2024) Ling-Gui-Zhu-Gan Granules Reduces Obesity and Ameliorates Metabolic Disorders by Inducing White Adipose Tissue Browning in Obese Mice. Frontiers in Physiology, 15, Article ID: 1427722.
https://doi.org/10.3389/fphys.2024.1427722
[24] 宋幸铃, 周亚娜, 周慧敏, 等. 向楠教授运用温肾健脾化痰法治疗肥胖症经验浅析[J]. 中医临床研究, 2024, 16(27): 127-130.
[25] 周慧敏. 温肾健脾化痰方调控单纯性肥胖大鼠脂代谢及瘦素抵抗的机制研究[D]: [博士学位论文]. 武汉: 湖北中医药大学, 2017.
[26] 张艳佶, 黄伟, 李佳, 等. 电针对肥胖大鼠白色脂肪组织PGC-1α/Irisin/UCP1信号通路的影响[J]. 中华中医药杂志, 2022, 37(6): 3471-3474.
[27] 范晓露, 林青琰, 何勇宗, 等. “引气归元健脾胃”针法治疗单纯性肥胖疗效及对血清炎症因子、mTOR水平的影响[J]. 针灸临床杂志, 2018, 34(10): 5-9.
[28] 陈娇妍, 林兰燕, 何毅琪. 中医综合疗法对单纯性肥胖的疗效观察[J]. 中国医药指南, 2025, 23(7): 152-155.